<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426021</url>
  </required_header>
  <id_info>
    <org_study_id>MLN1202/CPH-001</org_study_id>
    <secondary_id>U1111-1169-0038</secondary_id>
    <secondary_id>JapicCTI-152874</secondary_id>
    <nct_id>NCT02426021</nct_id>
  </id_info>
  <brief_title>Phase 1 Single Subcutaneous Dose Study of MLN1202</brief_title>
  <official_title>A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate the safety, pharmacokinetics, and
      pharmacodynamic effect of a single dose of MLN1202 in healthy Japanese male adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single dose, phase 1 study in healthy Japanese and Caucasian male adults.

      Japanese subjects will be assigned to Cohort J1 (at a dose of 75 mg), Cohort J2 (105 mg),
      Cohort J3 (150 mg), or Cohort J4 (450 mg) in a randomized, double-blind, placebo-controlled
      manner, while Caucasian subjects to Cohort C1 (at a dose of 75 mg) or Cohort C2 (150 mg) in
      an open-label manner.

      Takeda has made a business decision to terminate this study due to portfolio
      re-prioritization. There were no safety or efficacy concerns.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business decision; No Safety or Efficacy Concerns
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events</measure>
    <time_frame>Up to Day 37</time_frame>
    <description>The adverse event is defined as any unfavorable and unintended sign, symptom, or disease that develops when a drug is administered, irrespective of the causal relationship to the drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of MLN1202</measure>
    <time_frame>Up to Day 37</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) of MLN1202 in serum</measure>
    <time_frame>Up to Day 37</time_frame>
    <description>Area under the serum concentration-time curve during a dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum monocyte chemoattractant protein-1 (MCP-1) concentrations</measure>
    <time_frame>Up to Day 37</time_frame>
    <description>Serum MCP-1 concentrations will be measured at each protocol-specified time point, when blood samples are collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in monocyte count from baseline</measure>
    <time_frame>Up to Day 37</time_frame>
    <description>The absolute monocyte count will be determined at each protocol-specified time point, when blood samples are collected.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Japanese and Caucasian Male Adults</condition>
  <arm_group>
    <arm_group_label>Cohort J1: MLN1202 (75 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (75 mg) in 6 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J1: placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of placebo in 2 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J2:MLN1202 (105 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (105 mg) in 6 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J2: placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of placebo in 2 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J3: MLN1202 (150 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (150 mg) in 6 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J3: placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of placebo in 2 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J4: MLN1202 (450 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (450 mg) in 6 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J4: placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of placebo in 2 healthy Japanese male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C1: MLN1202 (75 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (75 mg) in healthy Causacian male adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C2: MLN1202 (150 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of MLN1202 (150 mg) in healthy Causacian male adults</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN1202</intervention_name>
    <description>Subcutaneous administration of MLN1202</description>
    <arm_group_label>Cohort J1: MLN1202 (75 mg)</arm_group_label>
    <arm_group_label>Cohort J2:MLN1202 (105 mg)</arm_group_label>
    <arm_group_label>Cohort J3: MLN1202 (150 mg)</arm_group_label>
    <arm_group_label>Cohort J4: MLN1202 (450 mg)</arm_group_label>
    <arm_group_label>Cohort C1: MLN1202 (75 mg)</arm_group_label>
    <arm_group_label>Cohort C2: MLN1202 (150 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN1202 Placebo</intervention_name>
    <description>Subcutaneous administration of MLN1202 placebo</description>
    <arm_group_label>Cohort J1: placebo</arm_group_label>
    <arm_group_label>Cohort J2: placebo</arm_group_label>
    <arm_group_label>Cohort J3: placebo</arm_group_label>
    <arm_group_label>Cohort J4: placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          2. The participant signs and dates a written informed consent form (ICF) prior to the
             initiation of any study procedures.

          3. The participant is a healthy adult man who is defined as Japanese (all parents and
             grandparents of the participant are Japanese) or Caucasian (all parents and
             grandparents of the participant are Caucasian).

          4. The participant is between 20 and 45 years of age at the time of informed consent.

          5. The participant has a body weight of at least 50 kg and has a body mass index (BMI)
             between 18.5 and 25.0 kg /m2 when the participant is Japanese or between 18.5 and 30.0
             kg /m2 when the participant is Caucasian at the time of screening and baseline
             examination.

          6. A male participant who is sexually active with a female partner of childbearing
             potential and who has not received contraceptive therapy agrees to use adequate
             contraception from the time of informed consent until 12 weeks (84 days) after
             administration of the study drug.

        Exclusion Criteria:

          1. The participant has received any other investigational compound within 16 weeks (112
             days) prior to administration of the study drug.

          2. The participant has previously received agents containing MLN1202, a monoclonal
             antibody or monoclonal antibody fragment.

          3. The participant has been vaccinated within 4 weeks (28 days) prior to administration
             of the study drug or is planning to be vaccinated during the study period.

          4. The participant is a study site employee or immediate family member of the employee,
             or may consent under duress.

          5. The participant has poorly-controlled, clinically significant neurologic,
             cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, or
             endocrine disease, hemorrhagic disorder or other abnormalities which may impact the
             ability of the participant to participate or potentially confound the study results.

          6. The participant has recurrent serious or poorly-controlled infection and is considered
             to have difficulty participating in the study by the investigator.

          7. The participant has a history of hypersensitivity or allergies to MLN1202 or additives
             contained in MLN1202 preparations.

          8. The participant has a history of hypersensitivity or allergies to monoclonal
             antibodies other than MLN1202.

          9. The participant has positive results in urine drug tests at screening.

         10. The participant has a history of drug abuse (defined as any illicit drug use) or a
             history of alcohol dependence within 2 years prior to the study visit at screening or
             is unwilling to agree to abstain from alcohol and drugs throughout the study period.

         11. The participant requires any excluded medication or food products listed in the
             Excluded Medications and Dietary Products (see section 7.3) during the study period.

         12. The participant intends to donate sperm during the study period or period until 12
             weeks (84 days) after administration of the study drug.

         13. The participant has a history of cancer.

         14. The participant has, is suspected of having, or has a history of active tuberculosis
             or latent tuberculosis infection.

         15. The participant has a positive test result for hepatitis B surface antigen (HBsAg),
             hepatitis B virus antibody (hepatitis B surface antibody [HBsAb]/ hepatitis B core
             antibody [HBcAb]), hepatitis C virus (HCV) antibody, human immunodeficiency virus
             (HIV) antibody/antigen, or serological reactions for syphilis at screening. This does
             not include the participant who has a positive test result only for HBsAb due to HBV
             vaccination.

         16. The participant has used nicotine-containing products (cigarettes, pipes, cigars,
             chewing tobacco, nicotine patches, or nicotine gum, etc.) within 4 weeks (28 days)
             prior to administration of the study drug.

         17. The participant has poor peripheral venous access.

         18. The participant has undergone whole blood collection of at least 200 mL within 4 weeks
             (28 days) or at least 400 mL within 12 weeks (84 days) prior to administration of the
             study drug.

         19. The participant has undergone whole blood collection of at least 800 mL in total
             within 52 weeks (364 days) prior to administration of the study drug.

         20. The participant has undergone blood component collection within 2 weeks (14 days)
             prior to administration of the study drug.

         21. The participant has any clinically significant electrocardiographic (ECG)
             abnormalities at the time of screening or baseline examination.

         22. The participant has abnormal laboratory values that suggest a clinically significant
             underlying disease, or the participant has the following lab abnormalities at the time
             of screening or baseline examination: alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) &gt;1.5 Ã— the upper limits of normal, or differential white blood
             count (monocytes) &lt; the lower limit of normal.

             The following criteria will be evaluated by laboratory tests at the screening: insulin
             (fasting), parathyroid hormone (PTH) (intact).

         23. The participant has systolic blood pressure &lt;80 mmHg or diastolic blood pressure &lt;45
             mmHg, or systolic blood pressure &gt;160 mmHg or diastolic blood pressure &gt;100 mmHg at
             the time of screening, baseline examination or examination prior to administration of
             the study drug.

         24. The participant is receiving treatment for a wound and is, in the opinion of the
             investigator, unsuitable to participate in the study.

         25. The participant is scheduled to undergo surgery within 12 weeks (84 days) after
             administration of the study drug.

         26. In the opinion of the investigator, the participant is unlikely to comply with the
             protocol or is unsuitable for any other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

